Base editing marches on the clinic
By Michael Eisenstein,
Nature
| 05. 09. 2022
This year could see the first trials of therapies employing base editing that introduce precise single-nucleotide changes into patient genomes.
Two companies, Beam Therapeutics and Verve Therapeutics, are leading the charge of base editing therapies to the clinic. Last November, Beam got the green light from the US Food and Drug Administration (FDA) for its upcoming BEACON-101 trial that will use base editing to restore expression of fetal globin in bone marrow stem cells. In parallel, Verve is preparing to embark on an in vivo base editing trial to treat patients who have experienced a heart attack and have abnormally high cholesterol levels by targeting the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene, after obtaining promising results from preclinical work in rodents and non-human primates. “We’re optimistic about dosing our first patients in the second half of this year,” says Verve CEO and co-founder Sekar Kathiresan. The rapid progress of base editing programs is attracting interest from major pharmaceutical companies: in January, Beam entered a collaboration with Pfizer that could net the company up to $1.3 billion.
Beam’s rapid progress to the clinic — using technology developed just six years ago — has been built on the shoulders... see more
Related Articles
By Kudrat Wadhwa , The Verge | 06.14.2022
When Arianna Huhn experienced complications with her first pregnancy, she signed up for a clinical trial, one that required her to submit family DNA samples for research. Her parents, Gail and George Fogelman, agreed. But shortly after, they asked her...
By Mohana Basu , The Print | 05.31.2022
New Delhi: For centuries, matching janampatris and kundalis, or natal charts, has been an important aspect of the matchmaking process in India. It has been said to determine whether a couple is well-suited. But couples these days are opting for...
By Carey Goldberg, Bloomberg | 05.26.2022
Photo by Warren Umoh on Unsplash
Simone Collins knew she was pregnant the moment she answered the phone. She was on her sixth round of in vitro fertilization treatments and had grown used to staffers at Main Line Fertility starting...
By Laura Hercher, Scientific American | 06.01.2022
In clinics today, fertility patients using in vitro fertilization (IVF) are routinely advised to pay for an expensive supplemental test called preimplantation genetic testing for aneuploidy (PGT-A), in which a handful of cells are removed from the embryo to examine...